| abstract |
Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for enginerring Cas9 and Cas9 variants that have increased activity on target sequences that do not contain the canonical PAM sequence. In some embodiments, fusion proteins comprising such Cas9 variants and nucleic acid editing domains, e.g., deaminase domains, are provided. |